The people behind the ideas.
The ideas behind the companies.

Unstructured
Unstructured’s
Brian Raymond
on tackling engineering bottlenecks
Rover
Rover’s
Aaron Easterly
on the love of pets and finding the right partners
Pulumi
Pulumi’s
Joe Duffy
on bringing more power to developers
OctoAI
OctoAI’s
Luis Ceze
on bringing ML to all platforms
Common Room
Common Room’s
Linda Lian
on integrating community into your company
Spotnana
Spotnana’s
Sarosh Waghmar
on challenging a decades-old industry
Statsig
Statsig’s
Vijaye Raji
on using data to build better products
RelationalAI
RelationalAI’s
Molham Aref
on finding investors who believe in your passion
Highspot
Highspot’s
Robert Wahbe
on customers, AI, and building relationships that last
Crowd Cow
Crowd Cow’s
Elizabeth Liu
on the power of e-commerce to transform an industry
Nautilus Bio
Nautilus Bio’s
Sujal Patel and Parag Mallick
on the proteome
SeekOut
SeekOut’s
Anoop Gupta
on hiring and untapped talent pools
Pendulum
Pendulum’s
Mark Listes
on finding hidden narratives in social media
Flexe
Flexe’s
Karl Siebrecht
on transforming the logistics industry

Company List

  • Envisagenics
    Envisagenics is an Artificial Intelligence-driven biotechnology company that focuses on the discovery of novel RNA splicing variants that cause cancer and other genetic diseases. Its principal technology is the SpliceCore® discovery platform. The platform re-envisions the human genome with a validated exon-centric approach, combined with machine learning algorithms and high-performance computing. It is up to 250 times more likely to discover novel targets than gene-centric discovery tools. Using innovative technology and RNA analysis expertise, Envisagenics accelerates the development of highly specific therapeutics that modulate RNA splicing events that drive pathogenesis of oncology, neurodegenerative, and metabolic disorders.
    Initial Investment
    2018
    Envisagenics is an Artificial Intelligence-driven biotechnology company that focuses on the discovery of novel RNA splicing variants that cause cancer and other genetic diseases. Its principal technology is the SpliceCore® discovery platform. The platform re-envisions the human genome with a validated exon-centric approach, combined with machine learning algorithms and high-performance computing. It is up to 250 times more likely to discover novel targets than gene-centric discovery tools. Using innovative technology and RNA analysis expertise, Envisagenics accelerates the development of highly specific therapeutics that modulate RNA splicing events that drive pathogenesis of oncology, neurodegenerative, and metabolic disorders.
    Founders
    Maria Luisa Pineda
    Martin Akerman
    Initial Investment
    2018
  • Nautilus Bio
    Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
    Initial Investment
    2018
    Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
    Founders
    Sujal Petal
    Parag Mallick
    Investment Journey
    Public June 2021
    NASDAQ: NAUT
    Initial Investment
    2018
  • Ovation
    Ovation is a next-generation clinical informatics company.
    Initial Investment
    2019
    Ovation is a next-generation clinical informatics company.
    CEO
    Curt Medeiros
    Initial Investment
    2019
  • Proof Diagnostics
    Proof is a startup working to make powerful CRISPR-based molecular testing affordable and accessible to everyone
    Initial Investment
    2020
    Proof is a startup working to make powerful CRISPR-based molecular testing affordable and accessible to everyone
    Founders
    Feng Zhang
    Jonathan Gootenberg
    Omar Abudayyeh
    Siddharth Shenai
    Initial Investment
    2020
  • TwinStrand
    TwinStrand Biosciences is a Seattle genomics company building a platform around Duplex Sequencing, a proprietary process that helps physicians, patients and drug researchers make life saving decisions faster based on DNA data.
    Initial Investment
    2019
    TwinStrand Biosciences is a Seattle genomics company building a platform around Duplex Sequencing, a proprietary process that helps physicians, patients and drug researchers make life saving decisions faster based on DNA data.
    Founder
    Jesse Salk
    Initial Investment
    2019